FDA Grants Priority Review to Adaptimmune's T-Cell Therapy for Advanced Synovial Sarcoma

Posted on by admin
1 min read

The biologics license application for afamitresgene autoleucel, an engineered T-cell receptor drug, was assigned a PDUFA date of August 4, 2024.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours